Treatment-resistant depression

Psychotherapy and Psychosomatics

Volumn 67, Issue 2, 1998, Pages 61-70

  Ananth, Jambur ^a  

^a HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

Antidepressant drugs; Depressive disorder; Lithium and thyroid augmentation; Resistant depression; TCA and SSRI combinations; Treatment

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BROFAROMINE; CLOMIPRAMINE; DESIPRAMINE; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; LITHIUM; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NEUROLEPTIC AGENT; NORTRIPTYLINE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; TRANYLCYPROMINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ARTICLE; DEPRESSION; ELECTROCONVULSIVE THERAPY; FAMILY HISTORY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MEDICAL DECISION MAKING; PSYCHOTHERAPY; SIDE EFFECT;

ADJUVANTS, PHARMACEUTIC; ANTIDEPRESSIVE AGENTS; DEPRESSION; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; HUMANS; LITHIUM;

EID: 0031913580     PISSN: 00333190     EISSN: None     Source Type: Journal    
DOI: 10.1159/000012261     Document Type: Article

References (113)

1. Workman EA, Short DD: Atypical antidepressants versus imipramine in the treatment of major depression: A meta-analysis. J Clin Psychiatry 1993;54:5-12.
2. Fawcett J: Antidepressants: Partial response in chronic depression. Br J Psychiatry 1994; 165(suppl 26):37-41.
3. Keller MB, Klerman GL, Lavori PW, Coryell W. Eddicott J, Taylor J: Long term outcome of major depression. JAMA 1984;252:788-792.
4. Ananth J, Ruskin RP: Treatment of intractable depression. Int Pharmacopsychiatry 1974;9: 218-229.
5. Burrows GD, Norman TR, Judd FK: Definition and differential diagnosis of treatment-resistant depression. Int Clin Psychopharmacol 1994:9(suppl 2):5-10.
6. Thase ME, Frank E, Mallinger AG, Hamer T, Kupfer DJ: Treatment of imipramine-resistant recurrent depression. III. Efficacy of mono-amine oxidase inhibitors. J Clin Psychiatry 1992;53:5-11.
7. Stoudemire A: Expanding psychopharmacologic treatment options for the depressed medical patient. Psychosomatics 1995;36:S19-26.
8. Greenhouse JB, Kupfer DJ, Frank E, Jarrett DB, Rejman KA: Analysis of time to stabilization in the treatment of depression: Biological and clinical correlates. J Affect Disord 1987; 13:259-266.
9. van Dyck MJ: Treatment resistant depression: A critique of current approaches. Aust N Z J Psychiatry 1994;28:34-41.
10. Hall RCW, Gardner ER, Popkin MK, Lecann AF, Stickney SK: Unrecognized physical illness prompting psychiatric admission: A prospective study. Am J Psychiatry 1981;138:629-635.
11. Patton SB, Love EJ: Drug induced depression. Psychother Psychosom 1997;66:63-73.
12. Zelnik T: Depressive effects of drugs: in Cameron OG (ed): Presentations of Depression: Depression in Medical and Other Psychiatric Disorders. New York, Wiley, 1987, pp 335-399.
13. Nelsen MR, Dunner DL: Clinical and differential diagnostic aspects of treatment resistant depression. J Psychiatr Res 1995;29:43-50.
14. Sharma V, Mazmanian D, Persad E, Kueneman K: A comparison of comorbid patterns in the treatment-resistant unipolar and bipolar depression. Can J Psychiatry 1995;40:270-274.
15. Keller MB, Lavori PW, Klerman GL, Andreasen NC, Endicott J, Coryell W, Fawcett J, Rice JP, Hirschfeld RMA: Low levels and lack of predictors of somatotherapy and psychotherapy received by depressed patients. Arch Gen Psychiatry 1986;43:458-466.
16. Phillips KA, Nierenberg AA: The assessment and treatment of refractory depression. J Clin Psychiatry 1994;55:20-26.
17. Scott J: Epidemiology, demography and definitions. Int Clin Psychopharmacol 1991;6:1-12.
18. Pare CMB, Mark JW: Differentiation of two genetically specific types of depression by the response to antidepressant drugs. J Med Genet 1971;8:306-309.
19. O'Reilly RL, Bogue L, Singh SM: Pharmaco-genetic response to antidepressants in a multi-case family with affective disorder. Biol Psychiatry 1994;36:461-471.
20. Charney DS. Price LH, Heninger GR: Desipramine-yohimbine combination treatment refractory depression. Arch Gen Psychiatry 1986;43:1155-1161.
21. Reimherr FW, Woods DR, Byerley B, Brainard J, Grosser BI: Characteristics of responders to fluoxetine. Psychopharmacol Bull 1984;20:70-72.
22. Kielholz P: Treatment of therapy resistant depression with drip infusions of chlorimipramine; in Zohar J, Belmaker RH (eds): Treating Resistant Depression. New York, PMA Publishing Corp, 1987, pp 389-396.
23. Stern WC, Haarto-Truax N, Bauer N: Efficacy of bupropion in tricyclic resistant or intolerant patients. J Clin Psychiatry 1983;44:148-152.
24. Cole JO, Schatzberg AF, Sniffin C, Zolner J, Cole JP: Trazodone in the treatment of resistant depression: An open study. J Clin Psychopharmacol 1981;1(suppl):49-54.
25. Beasley CM, Sayler ME, Cunningham GE, Weiss AM, Masica DN: Fluoxetine in tricyclic refractory major depressive disorder. J Affect Disord 1990;20:193-200.
26. Delgado PL, Price LH, Charney DS, Heninger GR: Efficacy of fluvoxamine in treatment resistant depression. J Affect Disord 1988;15:55-60.
27. Nolen WA, Van de Putte JJ, Dijken WA, Kamp JS, Blansjaar BA, Kramer HJ, Haffmans J: Treatment strategy in depression. I. Nontricyclic and selective reuptake inhibitors in resistant depression: A double blind partial cross over study on the effects of oxaprotiline and fluvoxamine. Acta Psychiatr Scand 1988; 78:668-675.
28. White K, Wykoff W, Tynes LL, Schneider L, Zemansky M: Fluvoxamine in the treatment of tricyclic resistant depression. Psychiatr J Univ Ottawa 1990;15:156-158.
29. Peselow ED, Filipi AM, Goodnick P, Barouche F, Fieve RR: The short and long term efficacy of paroxetine HCL: B. Data from a double blind cross over study and from a year long trial vs imipramine and placebo. Psychopharmacol Bull 1989;25:272-276.
30. Gagliano CA, Muller PGM, Gourie J, LeRoux JF: The therapeutic effects of paroxetine: a) an open study in patients with major depression not responding to antidepressants; b) a double blind comparison with amitriptyline in depressed patients. Acta Psychiatr Scand 1993; 80:130-131.
31. Nolen WA, Hoencamp E, Bouvy PF, Haffmans PM: Reversible monoamine oxidase-A inhibitors in resistant major depression. Clin Neuro-pharmacol 1993:16(suppl 2):69-76.
32. Hoencamp E, Haffmans PMJ, Dijken WA, Hoogduin CAL, Nolen WA, van Dyck R: Brofaromine versus lithium addition to maprotiline. A double-blind study in maprotiline refractory depressed outpatients. J Affect Disord 1994;30:219-227.
33. Nolen WA, Haffman PM, Bouvy PF, Duivenvoorden HJ: Monoamine oxidase inhibitors in resistant major depression. A double-blind comparison of brofaromine and tranylcypromine in patients resistant to tricyclic antidepressants. J Affect Disord 1993;28:189-197.
34. Volz HP, Faltus F, Magyar I, Moller HJ: Brofaromine in treatment resistant depressed patients - a comparative trial versus tranylcypromine. J Affect Disord 1994;30:209-217.
35. Murphy DL, Cohen RM, Sunderland T, Mueller E: Selective monoamine oxidase inhibitors in treatment resistant depression; in Zohar J, Belmaker RH (eds): Treating Resistant Depression. New York, NY Spectrum Press, 1987, pp 257-268.
36. Georgotas A, Friedman E, McCarthy M, Mann J. Krakowski M, Siegel R, Ferris S: Resistant geriatric depressions and therapeutic response to monoamine oxidase inhibitors. Biol Psychiatry 1983;18:195-205.
37. Sunderland T, Cohen RM, Molchan S, Lawlor BA, Mellow AM, Newhouse PA, Tariot PN, Mueller EA, Murphy DL: High dose seligiline in treatment resistant older depressive patients. Arch Gen Psychiatry 1994;51:607-615.
38. Nierenberg AA, Feighner JP, Rudolph R, Cole JO, Sullivan J: Venlafaxine for treatment-resistant unipolar depression. J Clin Psychopharmacol 1994;14:419-423.
39. Brown WA, Harrison W: Are patients who are intolerant to one SSRI intolerant to another? Psychopharmacol Bull 1992;28:253-256.
40. Weilburg JB, Rosenbaum JF, Biederman J, Sachs GS, Pollack MH, Kelly K: Fluoxetine added to non-MAOI antidepressants converts nonresponders to responders: A preliminary report. J Clin Psychiatry 1989;50:447-449.
41. Nierenberg AA, White K: What next? A review of pharmacological strategies for treatment resistant depression. Psychopharmacol Bull 1990;26:429-460.
42. Westermeyer J: Fluoxetine-induced tricyclic toxicity: Extent and duration. J Clin Pharmacol 1991;31:388-392.
43. Wetzel H, Hartter S, Szegedi A: Fluvoxamine co-medication to tricyclic antidepressants: Metabolic interactions, clinical efficiency and side effects. Pharmacopsychiatry 1993;26:211.
44. Seth R, Jennings AL. Bindman J, Phillips J, Bergmann K: Combination treatment with noradrenaline and serotonin reuptake inhibitors in resistant depression. Br J Psychiatry 1992;161:562-565.
45. Zajecka JM, Jeffries H, Fawcett J: The efficacy of fluoxetine combined with a heterocyclic antidepressant in treatment resistant depression: A retrospective analysis. J Clin Psychiatry 1995;56:338-343.
46. Fava M, Rosenbaum JF, McGrath PJ, Stewart JW, Amsterdam JD, Quitkin FM: Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: A double blind controlled study. Am J Psychiatry 1994;151: 1372-1374.
47. Glassman AH, Cantor SJ, Shostak M: Depressoin delusions and drug response. Am J Psychiatry 1975;132:716-719.
48. Nelson C: The use of antipsychotic drugs in the treatment of depression; in Zohar J, Belmaker RH (eds): Treating Resistant Depression. New York, PMA Publishing Group, 1987, pp 131-145.
49. Spiker DG, Weiss JC, Dealy RS, Griffin SJ, Hanin I, Neil NF, Perel JM, Rossi AJ, Soloff PH: The pharmacological treatment of delusional depression. Am J Psychiatry 1985;142: 430-436.
50. Stabl M, Kasas A, Blajev B, Bajetta G, Zochling R, Holsboer-Trachsler E, Realini R, Schaublin-Loidl M: A double-blind comparison of moclobemide and thioridazinc versus moclobemide and placebo in the treatment of refractory, severe depression. J Clin Psychopharmacol 1995;15:41S-45S.
51. Nelsen JC: The use of antipsychotic drugs in the treatment of depression; in Zohar J, Belmaker RH (eds): Treating Resistant Depression. New York, PMA Publishing, 1987, pp 131-146.
52. Tanum LH: Combination treatment with antidepressants in refractory depression. Int Clin Psychopharmacol 1994;9:37-40.
53. Lauritzen I, Clemmesen L, Klysner R, Loldrup D, Lunde M, Schaumburg E, Waarst S, Bech P: Combined treatment with imipramine and mianserin. Pharmacopsychiatry 1992;25:182-186.
54. Riise IS, Holm P: Concomitant isocarboxazid/ mianserin treatment of major depressive disorder. J Affect Disord 1984;6:175-179.
55. Graham PM: Combined mianserin and tranylcypromine. Br J Psychiatry 1988;153:415-417.
56. Ananth J, Luchins DJ: A review of combined tricyclic and MAOI therapy. Compr Psychiatry 1977;18:221-230.
57. White K, Simpson G: Combined MAOI-tricyclic antidepressant treatment: A reevaluation. J Clin Psychopharmacol 1981;2:264-282.
58. Davidson J, McLeod M, Law-Yone B, Linnoila M: A comparison of electroconvulsive therapy and combined phenelzine-amitriptyline in refractory depression. Arch Gen Psychiatry 1978;35:639-642.
59. Schmauss M, Kapfhammer HP, Meyr P, Hoff P: Combined MAO-inhibitor and tri (tetra) cyclic antidepressant treatment in therapy resistant depression. Prog Neuropsychopharmacol Biol Psychiatry 1988;142:430-436.
60. Berlanga C, Ortega-Soto HA: A 3-year follow up of a group of treatment resistant depressed patients with a MAOI-tricyclic combination. J Affect Disord 1995;34:187-192.
61. de Montigny C, Grunberg M, Mayer A, et al: Lithium induces rapid relief of symptoms in tricyclic antidepressant drug nonresponders. Br J Psychiatry 1981;138:252-256.
62. de Montigny C: Lithium addiction in treatment-resistant depression. Int Clin Pharmacol 1994;9(suppl 2):31-35.
63. Price LH, Charney DS, Heninger GR: Variability of response to lithium augmentation in refractory depression. Am J Psychiatry 1986; 143:1387-1392.
64. Katona CLE: Lithium augmentation in refractory depression. Psychiatr Dev 1988;2:153-171.
65. Lindgjaerde O, Edlund AH, Gormsen CA, Gottfries CG, Haugstad A, Herman IL, Hollnage P, Makimattila A, Rasmussen KE, Remvig J, Robak OH: The effect of lithium carbonate in combination with tricyclic antidepressants in endogenous depression. Acta Psychiatr Scand 1974;50:233-242.
66. Kantor D, McNevin S, Leichner P, Harper D, Krenn M: The benefit of lithium carbonate adjunct in refractory depression - fact or fiction? Can J Psychiatry 1986;31:416-418.
67. de Montigny C, Cournoyer G, Morissette R Langlois R, Caille G: Lithium carbonate addition in tricyclic antidepressant-resistant. Arch Gen Psychiatry 1983;40:1327-1334.
68. Heninger GR, Charney DS; Sternerg DE: Lithium carbonate augmentation of antidepressant treatment. Arch Gen Psychiatry 1993;40: 1335-1342.
69. Schopf J: Treatment of depression resistant to tricyclic antidepressants: Review of the literature. Pharmacopsychiatry 1989;22:174-182.
70. Katona CL, Abou-Saleh MT, Harrison DA, Nairac BA, Edwards DR, Lock T, Burns RA, Robertson MM: Placebo controlled trial of lithium augmentation of fluvoxetine and lofepramine. Br J Psychiatry 1995;166:80-86.
71. Austin SL, Souza FGM, Goodwin GM: Toxicity resulting from lithium augmentation of antidepressant treatment in the elderly patients. Br J Psychiatry 1991;159:510-514.
72. Kusnir SL: Lithium antidepressant combinations in the depressed physically ill geriatric patients. Am J Psychiatry 1986;143:378-379.
73. Stein G, Brnadt M: Lithium augmentation therapy in tricyclic-resistant depression. A controlled trial using lithium in low and normal doses. Br J Psychiatry 1993;162:634-640.
74. McCance-Katz E, Price LH, Charney DS, Heninger GR: Serotoninergic function during lithium augmentation of refractory depression. Psychopharmacology 1992;108:93-97.
75. Dinan TG: A rational approach to the non-responding depressed patient. Int Clin Psychopharmacol 1993;8:221-223.
76. Dinan TG: Lithium augmentation in sertraline resistant depression. Acta Psychiatr Scand 1993;88:300-301.
77. Hawley CJ, Roberts AG, Baldwin DS: Tolerability of combined treatment with lithium and fluoxetine: 14 cases treated under open conditions. Int Clin Psychopharmacol 1994;9:31.
78. Schopf J, Lemarchand T: Lithium addition in endogenous depressions resistant to tricyclic antidepressants or related drugs. Relation to the status of the pituitary-thyroid axis. Pharmacopsychiatry 1994;27:198-201.
79. Prangue AJ, Wilson IC, Rabon AM, Lipton MA: Enhancement of imipramine antidepressant activity by thyroid hormone. Am J Psychiatry 1969;126:457-469.
80. Coppen A, Whybrow PC, Noguera R, Maggs R, Prange AJ Jr: The comparative antidepressant value of l-tryptophan and imipramine with and without attempted potentiation by liothyronine. Arch Gen Psychiatry 1972;26:234-241.
81. Goodwin FK, Prange AJ Jr, Post RM. Muscettola G, Lipton MA: Potentiation of antidepressant effects of by l-triiodothyronine in tricyclic nonresponders. Am J Psychiatry 1982;139:34-38.
82. Joffe RT, Levitt AJ: Major depression and sub-clinical hypothyroidism. Psychoneuroendocrinology 1992;17:215-221.
83. Baumgartner A, Campos-Barros A, Meinhold H: Thyroid hormones and depressive illness: Implications for clinical and basic research; in Braverman LE, Visser TJ, Eber O, Langsteger W (eds): Fourth Thyroid Symposium - Brain and Thyroid. Graz, Acta Med Austriaca, 1992, pp 98-102.
84. Joffe RT, Sokolov STH, Singer W: Thyroid hormone treatment of depression. Thyroid 1995;5:235-239.
85. Thase ME, Kupfer DJ, Jarrett DB: Treatment of imipramine-resistant recurrent depression: 1. An open clinical trial of adjunctive L-triiodothyronine. J Clin Psychiatry 1989;50:385-388.
86. Gitlin MJ, Weiner H, Fairbanks L, Hershman JM, Friedfeld N: Failure of T3 to potentiate tricyclic antidepressant response. J Affect Disord 1987;13:267-272.
87. Pigott TA, Pato MT, L'Heureux F, Hill J, Grover GN, Bernstein SE, Murphy DL: A controlled comparison of adjuvant lithium carbonate or thyroid hormone in clomipramine-treated patients with obsessive-compulsive disorder. J Clin Psychopharmacol 1991;11:242-248.
88. Nemeroff CB: Augmentation regimens for depression. J Clin Psychiatry 1991;52:21-27.
89. Joffe RT, Singer W: A comparison of triidothyronine and thyroxine in the potentiation of tricyclic antidepressants. Psychiatry Res 1990;32: 241-252.
90. Gupta S, Masand P, Tanguarry JF: Thyroid hormone supplementation of fluoxetine in the treatment of major depression. Br J Psychiatry 1991;159:866-867.
91. Joffe RT: Triidothyronine potentiation of fluoxetine in depressed patients. Can J Psychiatry 1992;37:48-50.
92. Blier P, de Montigny C: Current advances and trends in the treatment of depression. Trends Pharmacol Sci 1994;15:220-226.
93. Artigas F, Perez V, Alvarez E: Pindolol induces a rapid improvement in depressed patients treated with serotonin reuptake inhibitors. Arch Gen Psychiatry 1994;51:248-251.
94. Blier P, Bergerson R: Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J Clin Psychopharmacol 1995;15:217-222.
95. Wharton RN, Perel JM, Dayton PG, Malitz S: A potential clinical use for methylphenidate with tricyclic anidepressants. Am J Psychiatry 1971;127:1619-1625.
96. Glassman A, Perel J, Shostak M, et al: Clinical implications of imipramine plasma levels for depressive illness. Arch Gen Psychiatry 1977;34:197-204.
97. Hansgen KD, Vesper J, Ploch M: Multicenter double blind study examining the antidepressant effectiveness of the hypericum extract LI 160. J Geriatr Psychiatry Neurol 1994;7:15-18.
98. Witte B, Harrer G, Kaptan T, Podzuweit H, Schmidt U: Behandlung depressiver Verstimmungen mit einem hochkonzentrierten Hypericumpräparat. Eine multizentrische plazebocontrollierte Doppelblindstudie. Fortschr Med 1995;113:46-54.
99. Woelke H, Burkard G, Grunwald J: Benefits and risks of the hypericum extract LI 160: Drug monitoring study with 3250 patients. J Geriatr Psychiatry Neurol 1994;7:34-38.
100. Sarai K: Oriental medicine as therapy for resistant depression: Use of some herbal drugs in the Far East. Prog Neuropsychopharmacol Biol Psychiatry 1992;16:171-180.
101. Guaraldi GP, Fava M, Mazzi F, La Greca P: An open trial of methyltetrahydrofolate in elderly depressed patients. Ann Clin Psychiatry 1993;5:101-105.
102. Ghadirian AM, Engelsmann F, Dhar V, Filipini D, Keller R, Chouinard G, Murphy BE: The psychotropic effects of inhibitors of steroid biosynthesis in depressed patients refractory to treatment. Biol Psychiatry 1995;37: 369-375.
103. Varney NR, Garvey MJ, Cook BL, Campbell DA, Roberts RJ: Identification of treatment-resistant depressives who respond favorably to carbamazepine. Ann Clin Psychiatry 1993; 5:117-122.
104. Ripley HS, Shorr E, Papanicolaou GN: The effect of treatment of depression in the menopause with estrogen hormone. Am J Psychiatry 1940;96:905-915.
105. Klaiber EL, Broverman DM, Vogel W, Kobayashi T: Estrogen therapy for persistent depression in women. Arch Gen Psychiatry 1979;36:550-554.
106. Holsboer F, Benkert O, Demisch L: Changes in MAO activity during gestrogen treatment of females with endogenous depression. Mod Prob Pharmacopsychiatry 1978;11:164-176.
107. Oppenheim G: Drug induced rapid cycling. Possible outcomes and management. Am J Psychiatry 1982;139:939-941.
108. Inoue T, Tsuchiya K, Miura J, Sakakibara S, Denda K, Kasahara T, Koyama T: Bromocriptine treatment of tricyclic and heterocyclic antidepressant-resistant depression. Biol Psychiatry 1996;40:151-153.
109. Bouras N, Bridges KP: Bromocriptine in depression. Curr Med Res Opin 1990;8:150-153.
110. Silverstone T: Response to bromocriptine distinguishes bipolar from unipolar depressed patients. Lancet 1984;i:903-904.
111. Waehrens J, Gerlach J: Bromocriptine and imipramine in endogenous depression: A double blind controlled trial in outpatients. J Affect Disord 1981;3:193-202.
112. Fava GA: The concept of recovery in affective disorder. Psychother Psychosom 1996; 65:2-13.
113. Fava GA, Savron G, Grandi S, Rafanelli C: Cognitive behavioral management of drug-resistant major depressive disorder. J Clin Psychiatry 1997;58:278-282.